DrugPatentWatch Database Preview
NUZYRA Drug Profile
When do Nuzyra patents expire, and when can generic versions of Nuzyra launch?
Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. There are ten patents protecting this drug.
This drug has one hundred and ninety-nine patent family members in forty countries.
The generic ingredient in NUZYRA is omadacycline tosylate. One supplier is listed for this compound. Additional details are available on the omadacycline tosylate profile page.
Summary for NUZYRA
| International Patents: | 199 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Drug Prices: | Drug price information for NUZYRA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NUZYRA |
| DailyMed Link: | NUZYRA at DailyMed |
Generic Entry Opportunity Date for NUZYRA
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW NDA:
Dosage:
POWDER;INTRAVENOUS |
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NUZYRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Paratek Pharmaceuticals Inc | Phase 2 |
US Patents and Regulatory Information for NUZYRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NUZYRA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2010009693 | Start Trial |
| Japan | 2011102296 | Start Trial |
| Japan | 5940119 | Start Trial |
| Norway | 2271348 | Start Trial |
| Croatia | P20150584 | Start Trial |
| South Korea | 101835574 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
